Novavax: A Particular Growth Stock That Has the Potential to Outperform the Market

The bad news is that NVAX isn't outperforming the market today. The biotech company's stock has dropped 56% this year, while the S&P 500 has dropped roughly 6%. NVAX's stock has risen more than 3,400% in the last two years.
By: Medical Infralytix Pvt Ltd
 
CHAM, Switzerland - July 19, 2022 - PRLog -- Why has there been such a shift? As the business fell behind on regulatory filings for its Coronavirus vaccine candidate, investors lost trust in the company. NVAX has since gotten back on track. However, the stock market hasn't followed suit. Now for the good news, even if NVAX missed out on selling vaccine doses during the early phases of the pandemic, it still has long-term market-beating potential.

NVAX was one of the first businesses to enter clinical trials with a vaccine candidate. In addition, the United States put $1.6 billion towards the company's program at the start. Investors expected NVAX to be one of the first businesses to join the vaccine market as a consequence. When this did not materialize, many investors then abandoned the stock.

Of course, an early entry into this multibillion-dollar industry would have been ideal. Even a late arrival, is proving beneficial to NVAX. To begin with, the business has received orders for 110 million pills from the United States, as well as requests for up to 430 million doses from a variety of other nations. NVAX has also signed agreements to supply over a billion doses to low- and middle-income countries.

So far, the vaccine has been approved in more than 35 countries and NVAX has begun shipping it. As a result, revenue is starting to flow in. NVAX plans to generate $4 billion to $5 billion in revenue this year from vaccine sales, according to the company. Because the vaccine is NVAX's first and only marketable product, this is a huge issue.

The only source of uncertainty at the moment is that the corporation is still waiting for the United States to make a decision on its permission request. The United States, according to some, is a good example. The Food and Drug Administration may be dragging its feet in approving NVAX's candidate. Nonetheless, NVAX's data is solid and the company appears to have a decent chance of succeeding.

Catch up-to-date press release and more at Medical Infralytix Pvt Ltd services, do visit our website at https://meditherma.com/ or contact us thru email.

Contact
Samantha Smith
***@meditherma.com
End
Email:***@meditherma.com
Posted By:***@meditherma.com Email Verified
Tags:Medical Infralytix Pvt Ltd
Industry:Financial
Location:Cham - Cham - Switzerland
Subject:Reports
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Meditherma PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share